IP Library Granted Patent US 7,501,117
Granted Patent B2
US 7,501,117 · App. 11/166,288 · Granted Mar 10, 2009

Composition exhibiting a von Willebrand factor (vWF) protease activity comprising a polypeptide chain with the amino acid sequence AAGGILHLELLV

Assignee: Baxter Innovations GmbH
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,501,117
App. No.
11/166,288
Granted
Mar 10, 2009
Kind
B2
Abstract

The invention relates to vWF cleaving entities having a molecular weight of 180 kD, 170 kD, 160 kD, 120 kD or 110 kD and an N-terminal amino acid sequence of AAGGILHLELLV, vWF cleaving complexes and methods for their production.

Claims (8)

1. An isolated polypeptide exhibiting vWF protease activity and vWF binding activity, having a molecular weight between about 180 kD and about 120 kD as determined by SDS-PAGE under reducing conditions and comprising the amino acid sequence AAGGILHLELLV (SEQ ID NO:1), wherein the isolated polypeptide is encoded by a nucleic acid present in a cDNA library obtained from poly A + RNA isolated from a human.

2. The isolated polypeptide according to claim 1 , wherein said sequence is located at the N-terminus of the peptide chain.

3. The isolated polypeptide according to claim 1 , wherein said peptide has a molecular weight of about 180 kD.

4. The isolated polypeptide according to claim 1 , wherein said peptide has a molecular weight of about 170 kD.

5. The isolated polypeptide according to claim 1 , wherein said peptide has a molecular weight of about 160 kD.

6. The isolated polypeptide according to claim 1 , wherein said peptide has a molecular weight of about 120 kD.

7. The isolated polypeptide according to claim 1 , wherein said polypeptide comprises the amino acid sequence AAGGILHLELLVAVGPDVFQAHQEDTERYVLTNLNIGAELLRDPSLGAQFRVHLVKMVI LTEPEGAPNITANLTSSLLSVCGWSQTINPEDDTDPGHADLVLYITRFDLELPDGNRQVR GVTQLGGACSPTWSCLITEDTGFDLGVTI (SEQ ID NO:4).

8. A composition comprising the isolated polypeptide of claim 1 .

Assignments (4)
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNOR NAME, EXECUTION DATE, AND ADDRESS OF ASSIGNEE BAXALTA GMBH PREVIOUSLY RECORDED ON REEL 036366 FRAME 0445. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Apr 4, 2016
From: BAXALTA INNOVATIONS GMBH
To: BAXALTA INCORPORATED; BAXALTA GMBH
Reel/Frame 038345/0889 →
CHANGE OF NAME Recorded Mar 29, 2016
From: BAXTER INNOVATIONS GMBH
To: BAXALTA INNOVATIONS GMBH
Reel/Frame 038292/0447 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 17, 2015
From: BAXTER INNOVATIONS GMBH
To: BAXALTA GMBH; BAXALTA INCORPORATED
Reel/Frame 036366/0445 →
CHANGE OF NAME Recorded Jun 26, 2008
From: BAXTER AKTIENGESELLSCHAFT
To: BAXTER INNOVATIONS GMBH
Reel/Frame 021165/0796 →
Continuity (3)
Continuation 0983332800 · Apr 12, 2001
Continuation In Part 0972125400 · Nov 22, 2000
Related Publication 20050266528A1 · Dec 1, 2005